Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong sell rating to a sell rating in a research report report published on Wednesday, October 16th, BidAskClub reports.

VNDA has been the subject of a number of other research reports. Citigroup upgraded shares of Vanda Pharmaceuticals from a neutral rating to a buy rating and set a $19.00 target price for the company in a research report on Thursday, August 1st. ValuEngine upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a buy rating to a hold rating and set a $15.00 target price for the company. in a research report on Saturday, October 5th. Finally, Stifel Nicolaus restated a hold rating and issued a $17.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $26.71.

VNDA stock traded up $0.21 during trading on Wednesday, reaching $14.74. The stock had a trading volume of 787,900 shares, compared to its average volume of 762,937. The firm has a fifty day moving average price of $13.51 and a 200 day moving average price of $14.36. The company has a market capitalization of $719.20 million, a P/E ratio of 30.71 and a beta of 0.29. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $1.77. The company had revenue of $59.49 million during the quarter, compared to the consensus estimate of $58.33 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The firm’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period last year, the firm earned $0.13 EPS. On average, research analysts expect that Vanda Pharmaceuticals will post 0.3 EPS for the current fiscal year.

In related news, SVP Timothy Williams sold 2,575 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total transaction of $37,826.75. Following the transaction, the senior vice president now owns 57,425 shares of the company’s stock, valued at approximately $843,573.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard W. Dugan sold 15,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.85, for a total transaction of $222,750.00. Following the transaction, the director now directly owns 50,770 shares in the company, valued at approximately $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in VNDA. Alps Advisors Inc. increased its stake in shares of Vanda Pharmaceuticals by 32.0% in the third quarter. Alps Advisors Inc. now owns 26,782 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 6,498 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 45.4% in the third quarter. Russell Investments Group Ltd. now owns 250,083 shares of the biopharmaceutical company’s stock valued at $3,355,000 after buying an additional 78,037 shares during the period. California Public Employees Retirement System increased its stake in shares of Vanda Pharmaceuticals by 21.0% in the third quarter. California Public Employees Retirement System now owns 68,476 shares of the biopharmaceutical company’s stock valued at $909,000 after buying an additional 11,862 shares during the period. State of Tennessee Treasury Department increased its stake in shares of Vanda Pharmaceuticals by 8.9% in the third quarter. State of Tennessee Treasury Department now owns 39,392 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 3,215 shares during the period. Finally, Rice Hall James & Associates LLC increased its stake in shares of Vanda Pharmaceuticals by 2.7% in the third quarter. Rice Hall James & Associates LLC now owns 60,542 shares of the biopharmaceutical company’s stock valued at $804,000 after buying an additional 1,615 shares during the period.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: What is the role of the G-20?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News